Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form,...

Full description

Bibliographic Details
Main Author: Kirino E
Format: Article
Language:English
Published: Dove Medical Press 2014-11-01
Series:Adolescent Health, Medicine and Therapeutics
Online Access:http://www.dovepress.com/profile-of-aripiprazole-in-the-treatment-of-bipolar-disorder-in-childr-peer-reviewed-article-AHMT
_version_ 1819039135281709056
author Kirino E
author_facet Kirino E
author_sort Kirino E
collection DOAJ
description Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs) and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed state
first_indexed 2024-12-21T08:48:23Z
format Article
id doaj.art-4a9a23e5c1054636a19038302ebdc45a
institution Directory Open Access Journal
issn 1179-318X
language English
last_indexed 2024-12-21T08:48:23Z
publishDate 2014-11-01
publisher Dove Medical Press
record_format Article
series Adolescent Health, Medicine and Therapeutics
spelling doaj.art-4a9a23e5c1054636a19038302ebdc45a2022-12-21T19:09:45ZengDove Medical PressAdolescent Health, Medicine and Therapeutics1179-318X2014-11-012014default21122119315Profile of aripiprazole in the treatment of bipolar disorder in children and adolescentsKirino EEiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs) and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed statehttp://www.dovepress.com/profile-of-aripiprazole-in-the-treatment-of-bipolar-disorder-in-childr-peer-reviewed-article-AHMT
spellingShingle Kirino E
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
Adolescent Health, Medicine and Therapeutics
title Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
title_full Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
title_fullStr Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
title_full_unstemmed Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
title_short Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
title_sort profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
url http://www.dovepress.com/profile-of-aripiprazole-in-the-treatment-of-bipolar-disorder-in-childr-peer-reviewed-article-AHMT
work_keys_str_mv AT kirinoe profileofaripiprazoleinthetreatmentofbipolardisorderinchildrenandadolescents